Áttétes emlőrák: vizsgálatok itt: Ausztria
11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Feldkirch, Graz, Linz, Vienna
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Graz, Linz, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
- Where
- Innsbruck, Linz, Vienna, Wels
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Graz, Innsbruck, Linz, Vienna
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 2. fázisTaking peopleHER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
- Where
- Innsbruck
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Abscint NV/SA
See details and how to joinNCT06369831 · EU 2024-511419-22-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Krems An Der Donau, Linz, Salzburg, Vienna, Wels
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - 3. fázisTaking peopleElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Innsbruck, Linz, Schwaz, Vienna
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseTaking peopleDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Graz, Innsbruck, Klagenfurt, Leoben, Linz, Rankweil, Salzburg, Vienna, Vöcklabruck, Wels, Wiener Neustadt
- Életkor
- 18 év and over
- People
- 2295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732 - 2. fázisTaking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Graz, Linz, Vienna
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - 2. fázisTaking peopleA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Graz, Vienna
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - No phaseTaking peopleMetastatic Breast Cancer in Austria
- Where
- Braunau am Inn, Dornbirn, Feldkirch, Graz, Innsbruck, Kufstein, Leoben, Linz, Salzburg, Sankt Pölten, Steyr, Vienna, Wels
- Életkor
- 18 év and over
- People
- 5000
- Run by
- Arbeitsgemeinschaft medikamentoese Tumortherapie
See details and how to joinNCT03870620